About this episode

Dr. Andreas Hausmann interviews Dr. Othman Al-Sawaf about the CLL17 study and its implications for CLL therapy.

People in this episode

Host: Dr. Andreas Hausmann

Guest: Dr. Othman Al-Sawaf

Topics covered

• CLL therapy
• ASH Meeting
• clinical trials
• treatment strategies
• patient outcomes

Keywords

• CLL
• BTK-Inhibition
• therapies
• TP53
• MRD
• Pirtobrutinib
• Richter-Transformation

Mentioned in this episode

Organizations: ASH, CLL17, CD20-Antikörpern, CLL18, CAR-T-Zellen

More episodes of Hämatologie Shortcasts

• AML – Revolution oder Evolution? · February 27, 2026 · 26 min
• ASH 2025 - Aggressive B-Zell-Lymphome: Neue Optionen für ältere Patient:innen, Zelltherapien und Monitoring · February 5, 2026 · 18 min
• ASH 2025 – T-Zell-Lymphome: Neue Targets, frühe Rezidive und klinische Konsequenzen · January 19, 2026 · 29 min
• ASH 2025 – Epcoritamab & Co.: Wie sich die Therapie des follikulären Lymphoms verändert · December 19, 2025 · 20 min
• ASH 2025 - AML im Umbruch? · December 17, 2025 · 33 min
• ASH 2025 – Latebreaker · December 4, 2025 · 34 min

Explore listener stats, chart rankings, contacts and more on the Hämatologie Shortcasts podcast page.